Oncoinvent Asa · OSL:ONCIN
Oncoinvent Asa — Q3 2024 Earnings Presentation
23 slides from Oncoinvent Asa's earnings presentation, Nov 13, 2024
Slide 1: Advancing selective AXL inhibition in STK11m Non-Squamous NSCLC
Advancing selective AXL inhibition in STK11m Non-Squamous NSCLC Q3 2024 presentation
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation or forecasts will come to pass or that any forecast result constitute forward-looking statements. Forward-looking will be achieved, and you are cautioned not to place any statements are statements that are not historical fa
Slide 3: Q3 and post period highlights
Q3 and post period highlights • BGBC016 study in 1L Non-Squamous NSCLC STK11m: o Encouraging safety data seen at all three dose levels studied in Ph1b o Patients achieved plasma levels consistent with that of responders in the 2L NSCLC (BGBC008) study o Tempus collaboration on plan to provide novel
Slide 4: 1L STK11m Non-Squamous NSCLC: A Significant Opportunity
1L STK11m Non-Squamous NSCLC: A Significant Opportunity 4
Slide 5: Bemcentinib expected to address highest unmet needs
Bemcentinib expected to address highest unmet needs Current Treatment Practices: 1L Non-Squamous NSCLC 1. PD-L1 levels predicts response to Immunotherapy 2. Mutational status predicts response to Targeted Therapies ~31,000 pts per year** 2% 2% 3% 5% Currently 5% ALK Mutations Actionable MET Other Wi
Slide 6: STK11m patients highly correlated with PD-L1 neg
STK11m patients highly correlated with PD-L1 neg 6 Skoulidis, Nature, October 9, 2024
Slide 7: New data shows wide gap between efficacy of CIT dependent on STK11m status
New data shows wide gap between efficacy of CIT* dependent on STK11m status Multi-center, retrospective analysis of 439 1L NSCLC patients treated with pembrolizumab + doublet chemotherapy ORR 40.9 % 33.0% mOS 16.7 mos. 11.1 mos. P=0.002 STK11wt STK11m mPFS 7.0 mos. 4.8 mos. P=0.024 0 5 10 15 20 25 3
Slide 8: Large potential in >30,000 US/EU 1L STK11m NSCLC
Large potential in >30,000 US/EU 1L STK11m NSCLC 1L NS* NSCLC 31,620 pts STK11m Pts 30,400 pts - Actionable Mutations x Average x 14,300 USD Monthly Price x 10 mos. x Average . Mos. Treatment 8 ~4.3 Billion USD/Year *Non-Squamous Source: Company estimates
Slide 9: The case for AXL inhibition with bemcentinib in 1L STK11m NSCLC
The case for AXL inhibition with bemcentinib in 1L STK11m NSCLC 9
Slide 10: Bemcentinib: highly differentiated AXL inhibitor
Bemcentinib: highly differentiated AXL inhibitor Selective, potent – improved AXL inhibition with fewer side effects Monotherapy activity seen in multiple indications Extensive safety data base: studied in over 600 patients Proven combinations with chemotherapy and checkpoint inhibition Concentrates
Slide 11: Strong rationale for AXL inhibition in STK11m pts
Strong rationale for AXL inhibition in STK11m pts Immunosuppressed AXL Inhibition Restores Immunoresponsive Tumor STK11m Tumor Immune Response Presence of CD8+ T cells CD8+ T cell exclusion Presence of CD8+ T cells High PDL-1 expression Low/No PDL-1 expression Stimulatory dendritic cells Stimulatory
Slide 12: Ph2A of BGBC016 in active recruitment
Ph2A of BGBC016 in active recruitment Ph1b – 3 doses studied Ph1b/2a Overlapping Protocol First dose moved into Ph2a Second dose moved into Ph2a Ph1b (US) Dose Escalation Ph2a (US & EU) Expansion Study Phase 3 doses 2 doses 1L Advanced/Metastatic NS-NSCLC pts 40 1L STK11m NS-NSCLC pts Patient Popula
Slide 13: Ph1b enrollment complete with promising PK
Ph1b enrollment complete with promising PK Long duration of response BGBC016 plasma levels in “responder range” BGBC008 2L NSCLC pts (<4th Quartile) in BGBC008 BGBC016 Ph1b BGBC008 Q1 Q2 Q3 Q4 10 100 1000 [bemcentinib]plasma, ng/mL 13
Slide 14: Bemcentinib only AXL inhibitor in 1L NSCLC
Bemcentinib only AXL inhibitor in 1L NSCLC Specific to Company/MoA Current Phase* Specific to 1L? NSCLC Population STK11m pts? BGB/AXL inhibitor + anti-PD1+ chemo Ph 1b/2a STK11m AZ/anti-PD1+anti-CTLA4 Ph 3b No STK11m, KEAP-1m, KRASm Shanghai Shengdi /anti-PD1+anti- STK11m or KEAP1 or KRAS Ph2/3 No
Slide 15: Highly promising and differentiated treatment for 1L STK11m Non-Sq. NSCLC
Highly promising and differentiated treatment for 1L STK11m Non-Sq. NSCLC • STK11m patients now seen as a major underserved lung cancer patient population that requires new immuno-oncology approaches • AXL expression is a key driver of resistance to CPI and chemo in STK11m patients • STK11m patients
Slide 16: Pipeline update
Pipeline update Tilvestamab • Tilvestamab was developed by BGB specifically for development in fibrotic diseases • Extensive partnership discussions failed to identify an attractive licensing opportunity • Accordingly, the decision has been made to discontinue all tilvestamab activities ADCT-601 • U
Slide 17: BGB is focused on NSCLC
BGB is focused on NSCLC Ph2a Bemcentinib + SOC in 1L STK11m NSCLC patients Ph1b Bemcentinib + pacritinib in 2L+ Lung Adenocarcinoma • Univ. of Texas San Antonio Investigator Led Trial funded by NIH in partnership with BGB and Sobi • First patient in expected in late 2024/early 2025 17
Slide 18: Key financials and newsflow
Key financials and newsflow 18
Slide 19: Key financials Q3 2024
Key financials Q3 2024 (NOK million Q3 2024 Q3 2023 YTD 2024 YTD 2023 FY 2023 Operating revenues 0.0 0.0 0.2 0.0 0.4 Operating expenses 27.2 28.1 117.9 148.3 192.2 Operating profit (-loss) -27.2 -28.1 -117.7 -148.3 (191.8) Profit (-loss) after tax -24.8 -27.9 -110.7 -148.8 (190.4) Average cash use w
Slide 20: Newsflow expected in H2 2024 - H1 2025
Newsflow expected in H2 2024 - H1 2025 H2 2024 H1 2025 BGBC016 BGBC016 ü Complete enrollment of BGBC016 Ph1b • Phase 2a interim analyses ü Ph1b safety overview • Complete enrollment of Ph2a ü 2nd dose identified in Ph2a ü Establish synthetic control arm Other • First patient in NIH funded lung cance
Slide 21: Clear focus to unlock significant value potential
Clear focus to unlock significant value potential • Execution of BGBC016 in 1L STK11m NSCLC • Phase 1b showed acceptable safety of combination and expected plasma levels • Phase 2a on-going with all sites activated • Collaboration with Tempus AI provides relevant and innovative contextual control ar
Slide 22: The Company is committed to deliver on the strategy
The Company is committed to deliver on the strategy • Experienced and competent organization in place to execute on the BGBC016 study • David Colpman added to Board of Directors bringing strong background in licensing and M&A transactions • Board of Directors leading search for new CEO to lead curre
Slide 23: Address and contact details
A d d re s s Mo l l e n d a l s b a k ke n 9 , 5 0 0 9 B e rg e n , N o r way P h o n e Nu mb e r + 47 559 61 159 E - ma i l p o s t @b e rg e n b i o . co m 23